News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 120
- Sources here
- 16
- Companies here
- 14
Search results
Stored financial headlines
Active search
120 matching headlines
Ticker or company: BEIMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Beigene Ltd (ONC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Beigene Ltd (ONC), detailing its current price momentum score, support and resistance levels, and various technical indicator readings. It shows that the stock is currently suitable for range-bound swing trading, with a neutral signal based on moving …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Beigene Ltd (ONC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Beigene Ltd (ONC), noting its current valuation score is 5.88 and it ranks 355 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 67.69, which is significantly below its recent …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Beigene Ltd (ONC) Institutional Confidence
This article analyzes the institutional confidence in Beigene Ltd (ONC), noting its current institutional shareholding score of 3.00, ranking 192 out of 386 in its industry. The institutional shareholding proportion has increased by 17.61% quarter-over-quarter, with ETHSX being the largest shareholder. The article lists …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Beigene Ltd (ONC) Income Statement
This article provides the quarterly and annual income statements for Beigene Ltd (ONC), offering detailed financial data such as total revenue, operating expenses, and net income over several years. It includes key financial metrics and a FAQ section explaining how to interpret the income …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Beigene Ltd (ONC) Cash Flow
This article provides Beigene Ltd's (ONC) cash flow statement, offering detailed quarterly and annual data for operating, investing, and financing activities. It includes key figures such as net income from continuing operations, capital expenditures, and free cash flow over several years. The report also …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Beigene Ltd (ONC) Balance Sheet
This article provides Beigene Ltd's (ONC) balance sheet data, including quarterly and annual figures for assets, liabilities, and shareholders' equity. It details various financial metrics such as cash and short-term investments, receivables, inventory, current and non-current assets, and different categories of liabilities. The content …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Beigene Ltd (ONC) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Beigene Ltd's (ONC) dividend and stock split history. It notes that the company has distributed a total of $0.00 USD in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Beigene Ltd (ONC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Beigene Ltd (ONC), presenting data by business segment and geographical region. It shows that in FY2025Q3, products accounted for 97.35% of revenue, with BRUKINSA being the top contributor. Geographically, the United States accounted for the largest …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
BeOne Medicines Expands U.S. Manufacturing With $1 Billion Investment
(RTTNews) - BeOne Medicines Ltd. (ONC) announced a $300 million expansion of its flagship manufacturing and R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing its total U.S. manufacturing investment to more than $1 billion. The expansion will add small …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
BeiGene(ONC.US) Officer Sells US$34.59 Million in Common Stock
An officer at BeiGene (ONC.US) recently sold a significant amount of common stock, totaling US$34.59 million. This transaction indicates a notable insider sale activity at the company.
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position
Key Points CEO John Oyler sold nearly 110,000 American Depositary Shares for $34.6 million at a weighted average price of $315.28 per share. The shares were sold under a pre-established Rule 10b5-1 trading plan. John Oyler retains Ordinary Shares: 50,493,512 shares (direct and indirect).10 …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
BeiGene stock steadies as oncology revenue grows and losses narrow
BeiGene Ltd. reported strong oncology revenue growth in 2023, exceeding $2.1 billion, driven by product sales of key therapies like Brukinsa and tislelizumab. The Nasdaq-listed biotech company also managed to narrow its net loss despite significant ongoing investment in research and development and global …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Barclays Maintains BeiGene(ONC.US) With Buy Rating, Cuts Target Price to $403
Barclays has reiterated its Buy rating for BeiGene (ONC.US) but has reduced its price target from $420 to $403. This adjustment reflects a continued positive outlook on the company despite the lowered target price.
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%